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Abstract
Background: There are no time trends in prevalence, unawareness, treatment, and control of hypertension in Switzerland.
The objective of this study was to analyze these trends and to determine the associated factors.
Methods/Findings: Population-based study conducted in the Canton of Geneva, Switzerland, between 1999 and 2009.
Blood pressure was measured thrice using a standard protocol. Hypertension was defined as mean systolic or diastolic
blood pressure $140/90 mmHg or self-reported hypertension or anti-hypertensive medication. Unawareness, untreated
and uncontrolled hypertension was determined by questionnaires/blood pressure measurements. Yearly age-standardized
prevalences and adjusted associations for the 1999–2003 and 2004–2009 survey periods were reported. The 10-year survey
included 9,215 participants aged 35 to 74 years. Hypertension remained stable (34.4%). Hypertension unawareness
decreased from 35.9% to 17.7% (P,0.001). The decrease in hypertension unawareness was not paralleled by a concomitant
absolute increase in hypertension treatment, which remained low (38.2%). A larger proportion of all hypertensive
participants were aware but not treated in 2004–2009 (43.7%) compared to 1999–2003 (33.1%). Uncontrolled hypertension
improved from 62.2% to 40.6% between 1999 and 2009 (P = 0.02). In 1999–2003 period, factors associated with
hypertension unawareness were current smoking (OR= 1.27, 95%CI, 1.02–1.59), male gender (OR= 1.56, 1.27–1.92),
hypercholesterolemia (OR= 1.31, 1.20–1.44), and older age (OR 65–74yrs vs 35–49yrs = 1.56, 1.21–2.02). In 1999–2003 and
2004–2009, obesity and diabetes were negatively associated with hypertension unawareness, high education was
associated with untreated hypertension (OR= 1.45, 1.12–1.88 and 1.42, 1.02–1.99, respectively), and male gender with
uncontrolled hypertension (OR= 1.49, 1.03–2.17 and 1.65, 1.08–2.50, respectively). Sedentarity was associated with higher
risk of hypertension and uncontrolled hypertension in 1999–2003.
Conclusions: Hypertension prevalence remained stable since 1999 in the canton of Geneva. Although hypertension
unawareness substantially decreased, more than half of hypertensive subjects still remained untreated or uncontrolled in
2004–2009. This study identified determinants that should guide interventions aimed at improving hypertension treatment
and control.
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Introduction
Hypertension is one of the major causes of disease burden
worldwide [1]. It affects approximately 37–55% of the adult
population in Europe [2]. Hypertension is the most important
modifiable cardiovascular risk factor for stroke, coronary artery
disease, heart failure and end-stage renal disease, and it also
increases all-cause mortality [3].
Trends in hypertension prevalence differ according to geo-
graphic and population characteristics and definition of arterial
hypertension. In the United States, the last NHANES 1988–2008
analysis reported an increase in prevalence from 23.9% in 1988–
1994 to 28.5% in 1999–2000. The prevalence remained stable
since then [4]. The population-based prevalence of hypertension
was also stable (19.7%–21.6%) in Canada between 1992 and 2009
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[5]. Compared to North America, European countries have
a higher prevalence of hypertension [6]. In Switzerland, the
prevalence of hypertension, based on measured blood pressure
(BP), varied with age and gender between 20% and 50% [7,8].
There are no reliable recent trend summaries of hypertension
changes (taking into account anti-hypertensive drugs information)
from Europe [9].
To control the public health burden of hypertension, several
guidelines recommend the screening, treatment and control of
high BP [10,11]. Hypertension awareness, treatment and control
have generally increased in the last decades [4,5,12,13]. Yet, the
rates of uncontrolled hypertension remain greater than 50% in
recent reports [4,12,13]. Factors such as smoking, obesity,
education, alcohol consumption and age have been associated
with the risk of untreated and uncontrolled hypertension [7,14–
16].
In Switzerland, there are no recent time trends in hypertension
treatment, control and unawareness. We analyzed the 1999–2009
trends from a large ongoing population-based study conducted in
Switzerland.
Specifically, the aims of this study were to assess 10-year trends
changes in hypertension prevalence, unawareness, treatment and
control for the adult population living in the canton of Geneva,
Switzerland. We also aimed to identify factors associated with
these four outcomes.
Methods
Participants
The ‘Bus Sante´’ is an ongoing cross-sectional population-based
study, which collects information on cardiovascular risk factors,
diet and physical activity. Yearly, a representative stratified sample
of 500 men and 500 women from the population of the Geneva
Canton is recruited and studied [17]. Three stations receive
participants. The first two stations are fixed and are based within
the Geneva University Hospitals. The third station is a medical
mobile unit, which visits three parts of the canton of Geneva. Four
trained collaborators interview and examine participants. All
procedures are reviewed and standardized across technicians on
a regular basis.
Subjects are selected independently throughout each year to
represent the canton’s approximately 100’000 male and 100’000
female non-institutionalized residents aged 35 to 74 years. Eligible
subjects are identified using a standardized procedure using an
annual residential list established by the local government. This
listing includes all potential eligible participants except persons
living illegally in the country. Stratified random sampling based on
the list by gender within 10-year age strata is proportional to the
corresponding population distributions. Selected subjects are
mailed an invitation to participate, and, if they do not respond,
up to 7 telephone attempts are made at different times on various
days of the week. If telephone contact is unsuccessful, 2 more
letters are mailed. Subjects not reached are replaced using the
same selection protocol. Subjects who refuse to participate are not
replaced. Each participant receives several self-administered,
standardized questionnaires covering the risk factors for the major
lifestyle chronic diseases, socio-demographic characteristics, edu-
cational and occupational histories, and reproductive history for
women. The 1999–2009 mean participation rate was 60% (range:
55%–65%).
Measurements
Each participant brings along their filled-in questionnaires,
which are checked for correct completion by trained inter-
viewers (a full visit can be watched on http://
epidemiologiepopulation.hug-ge.ch/video_busSante.html). In
a temperature-controlled room, body weight is measured with
the subject lightly dressed without shoes using a medical scale
(precision 0.5 kg), and standing height is measured using
a medical gauge (precision 1 cm). BP is measured thrice in
the sitting position on the right arm after at least 10 minutes
rest using a standard protocol. Between 1999 and 2003, BP was
measured using a manual mercury sphygmomanometer. Since
2004, BP was measured using a validated automated oscillo-
metric sphygmomanometer (OmronH HEM-907, Matsusaka,
Japan).
Prevalence, Unawareness, Treatment and Control of
Hypertension (Figure S1)
Hypertension was defined as mean systolic and/or diastolic
BP$140/90 mmHg or self-reported hypertension or presence of
anti-hypertensive medication. We considered as unaware par-
ticipants with high BP values who responded negatively to the
question ‘‘Have you ever been told that you had high BP?’’
Self-reported anti-hypertensive medication in participants de-
termined treated hypertension. Uncontrolled hypertension was
defined as a mean systolic and/or diastolic BP$140/90 mmHg
based on the Seventh Joint National Committee (JNCVII) on
Detection, Evaluation, and Treatment of High Blood Pressure
[10].
Physical Activity and Alcohol Consumption
Physical activity levels were quantified using a physical activity
frequency questionnaire (PAFQ), developed in the Geneva general
adult population and validated using heart rate monitoring [18].
Sedentarity was defined as 10 or less percent of total daily energy
expenditure (EE) (kcal/day) spent in activities demanding
$4 MET as suggested elsewhere [19].
Alcohol consumption (kcal/day) was estimated using a validated
food frequency questionnaire [20,21]. Alcohol consumption was
categorized into tertiles (lower, middle, upper tertiles).
Education, Citizenship, Medical History and
Comorbidities
Self-reported information on education was categorized as high
(Maturity/Baccalaureat or university) and low (Elementary school
or apprenticeship). Citizenships were categorized as Swiss and
non-Swiss according to self-reported nationality. Self-reported
information on lifestyle, medical history and comorbidities in-
cluded smoking status (never smokers, ex-smokers, and current
smokers), history of myocardial infarction, diabetes, and hyper-
cholesterolemia. Diabetes and hypercholesterolemia were defined
as follows: positive responses to the questions: ‘‘Have you ever
been told that you had diabetes/high cholesterol?’’ and ‘‘If so, are
you taking a drug for it?’’.
Socioeconomic Status
Since 2005, socioeconomic information is collected in the ‘Bus
Sante´’ study. Self-reported monthly household income is collected
using the following ranges: ,39000 CHF; 39000–49999 CHF;
59000–69999 CHF; 79000–99499 CHF; 99500–139000 CHF;
.139000 CHF (Swiss Francs CHF<1.1 US$<0.80J as on
January 2012). Job position information was categorized as non-
manual, manager or independent; non-manual, employed;
manual, independent; manual, employed; women/man-at-home;
retired or jobless.
Trends in Hypertension in Geneva (Switzerland)
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Statistical Analyses
Statistical analyses were performed using Stata 11.0 (Stata
Corp, College Station, USA). Continuous variables were expressed
as mean 6 standard deviation (SD). Categorical variables were
expressed as number of subjects and percentage. To determine
whether the prevalence, unawareness, treatment and control of
hypertension changed between 1999 and 2009, yearly data were
used and trend test performed. To test the associations between
potential determinants (e.g. smoking status) and study outcomes
(e.g. untreated hypertension), period 1999–2003 and 2004–2009
were used. The periods were so defined because of the publication
of the last Joint National Committee (JNCVII) on Detection,
Evaluation, and Treatment of High Blood Pressure report (2003)
[10], and because of the change in BP measurement (1999–2003:
mercury sphygmomanometer; 2004–2009: automated oscillo-
metric sphygmomanometer). To adjust for the age (a major risk
factor of hypertension) structure between survey periods, we
reported age-standardized prevalence, using the 2010 Geneva
Census population. We determined the associations of character-
istics with hypertension, hypertension unawareness, untreated and
uncontrolled hypertension using multiple logistic regressions.
In the years 2005 through 2008 the annual average number of
participants was lower than the other years because another
cohort study was conducted relying on the same infrastructure.
This is why sample size is smaller for the 2004–2009 than for the
1999–2003 period. Trends in prevalence of hypertension,
hypertension unawareness, untreated and uncontrolled hyperten-
sion were further determined by income level in a sub-population
taking into account information on job position status.
Ethics
The ‘Bus Sante´’ study complied with the Declaration of Helsinki
and was approved by the Institutional Ethics Committee of the
University of Geneva (Paul Bovier, Bernard Baertschi, Patrick
Bovier, Jacquline Bursik, Be´at Stoll, Marinette Ummel). All
participants gave written informed consent.
Results
Population Characteristics
A total of 9,215 subjects were included in the analyses (50%
women). Overall mean age was 51.5 yrs (SD, 10.8). There were
4,402 subjects between 35–49 yrs (47.8%), 3,462 between 50–
64 yrs (37.6%) and 1,351 between 65–74 yrs (14.7%) (Table 1).
Forty-five percent of the subjects were never-smokers, 30% were
current smokers and 25% ex-smokers. Average BMI was 25.1 (SD
4.2) kg/m2. Twelve percent had a BMI of 30 kg/m2 or more
(obesity). Twenty-six percent had hypercholesterolemia, 6.1%
diabetes, 1.9% a history of myocardial infarction. About half of the
participants reported high education level.
Compared to participants, non-participants were more likely to
be women (52.2% vs 50.0%, p value ,0.001), older (52.7 years
(SD 11.1) vs 51.5 (SD 10.8), p value ,0.001) and to have the Swiss
citizenship (62.9% vs 54.2%, p value ,0.001). There was no
difference with respect to smoking status (47.0% vs 44.9% were
never smokers, 29.2% vs 29.7% were current smokers, and 23.9%
vs 25.3% were ex-smokers, p value = 0.06).
The mean systolic and diastolic BP were 125.9 mmHg (19.4)
and 78.0 mmHg (11.2), respectively. The percentages of partic-
ipants by BP categories were as follow: systolic and diastolic
BP,120/,80, 33.4%; systolic or diastolic BP 120–139/80–89,
38.1%; systolic or diastolic BP 140–159/90–99, 20.7%; and
systolic or diastolic BP$160/$100, 7.8%.
The number of participants were 6,020 (65.3%) and 3,195
(34.7%) in the 1999–2003 and 2004–2009 survey period, re-
spectively. The prevalence of smoking status, diabetes, hypercho-
lesterolemia, education level, Swiss citizenship, and alcohol
consumption differed significantly between the two periods. The
mean diastolic BP was lower in the second period than the first
period (79.1 vs 76.0, p,0.05), and the overall distribution of the
grades or stages of hypertension differed between the two periods.
Trends in Hypertension, Unawareness, Untreated and
Uncontrolled Hypertension Prevalences
The overall age-standardized prevalence of hypertension was
34.4%. This prevalence remained stable between 1999–2009
(Figure 1, Tables S1 and S2) in both men and women. The
prevalence of hypertension unawareness decreased between 1999
and 2009, in men and in women specifically (p,0.001). In 1999,
35.90% of hypertensive participants were unaware of having
hypertension, whereas 17.7% of hypertensive participants were
unaware of having hypertension in 2009., The increasing
tendancy of the prevalence of untreated hypertension observed
in men and in women specifically was only statistically significant
(from 53.9% to 61.8%, p= 0.04) when men and women
participants were combined and thus power increased. The
prevalence of uncontrolled hypertension decreased between 1999
and 2009 (p,0.05); from 62.2% to 40.6% in men and women
combined, from 60.6% to 49.6% in men, and from 72.2% to
37.8% in women.
Determinants of Hypertension
Multivariate associations of characteristics with hypertension
are reported by periods in Table 2. In the 1999–2003 period,
male gender, sedentarity, obesity, hypercholesterolemia, diabetes,
older age, and alcohol consumption were all positively associated
with the risk of hypertension. Compared to never and ex-smokers,
current smokers were less likely to have hypertension.
Similar associations were found in the 2004–2009 with the
exception of sedentarity, alcohol consumption, and education
level. The first two were not positively associated with hyperten-
sion in the second survey period. Of note, high education was
significantly negatively associated with hypertension in the second
survey period.
Determinants of Hypertension Unawareness
In the 1999–2003 period, current smokers were more likely to
be unaware of having hypertension compared to never and ex-
smokers. Male gender, hypercholesterolemia, older age were
positively associated with the risk of hypertension unawareness.
Participants with BMI $30 kg/m2 (and diabetes were less likely to
be unaware of having hypertension. In the 2004–2009 period, only
obesity and diabetes remained independently associated with
hypertension unawareness.
Determinants of Untreated Hypertension
In the first survey period, sedentarity, hypercholesterolemia,
and older age were associated with a lower risk of untreated
hypertension. Participants with high education were more likely to
have untreated hypertension than participants reporting low level
of education. Older age and education level remained associated
with untreated hypertension in the 2004–2009 period.
Determinants of Uncontrolled Hypertension
Male gender and sedentarity were associated with increased risk
of uncontrolled hypertension in the first survey period, while only
Trends in Hypertension in Geneva (Switzerland)
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male gender remained associated with uncontrolled hypertension
in the second survey period.
Prevalence of Hypertension, Unawareness, Untreated
and Uncontrolled Hypertension, by Monthly Household
Income and Job Position
Information on monthly household income and job position
collected since 2005 was available for 2,024 (22.0%) participants
whose main characteristics are presented in Table S3. The age-
standardized prevalence of hypertension, unawareness, untreated
and uncontrolled hypertension varied with job position (Table
S4). To adjust for the effect of job position, trends with household
monthly income were further adjusted for job position. After full
adjustment, no clear trends were found.
Prevalences in Mutually Exclusive Groups
Figure S2 illustrated the prevalences of the four mutually
exclusive groups among participants with hypertension: unaware;
aware, not treated; aware, treated, not controlled; aware, treated,
and controlled. The prevalences of these mutally exclusive groups
for the period 1999–2003 and 2004–2009 were respectively 38.6%
(809/2095) and 24.9% (272/1094), 33.2% (695/2095) and 43.8%
(479/1094), 17.0% (357/2095) and 18.9% (207/1094), 11.2%
(234/2095) and 12.4% (136/1094).
Table 1. Participants’ characterisitics, values are Mean (SD) or N (%).
ALL Period 1 Period 2
1999–2009 (N=9,215) 1999–2003 (N=6,020) 2004–2009 (N=3,195) P value
Age, mean, (yrs) 51.5 (10.8) 51.5 (10.8) 51.5 (10.9) 0.88
Age group
35–49yrs 4,402 (47.8) 2,874 (47.7) 1,528 (47.8) 0.89
50–64yrs 3,462 (37.6) 2,270 (37.7) 1,192 (37.3)
65–74yrs 1,351 (14.7) 876 (14.6) 475 (14.9)
Female 4,605 (50.0) 2,977 (49.5) 3043 (50.5) 0.17
Smoking status
Never smokers 4,140 (44.9) 2,681 (44.5) 1,459 (45.7) 0.001
Current smokers 2,739 (29.7) 1,741 (28.9) 998 (31.2)
Ex-smokers 2,336 (25.3) 1,598 (26.5) 738 (23.1)
BMI, mean, (kg/m2) 25.1 (4.2) 25.1 (4.2) 25.0 (4.2) 0.26
BMI, categories,
BMI ,25 kg/m2 4,852 (52.7) 3,160 (52.5) 1,692 (53.0) 0.91
BMI 25–29.9 kg/m2 3,273 (35.5) 2,147 (35.7) 1,126 (35.2)
BMI $30 kg/m2 1’090 (11.8) 713 (11.8) 377 (11.8)
Diabetes 563 (6.1) 343 (5.7) 220 (6.9) 0.02
Hypercholesterolemia 2,408 (26.1) 1,525 (25.3) 883 (27.6) ,0.0001
Myocardial infarction history 177 (1.9) 123 (2.0) 54 (1.7) 0.24
SBP, mm Hg, mean 125.9 (19.4) 126.1 (19.7) 125.5 (18.8) 0.13
DBP, mm Hg, mean 78.0 (11.2) 79.1 (11.0) 76.0 (11.2) ,0.0001
HTN stages ,0.0001
S/DBP$160/$100 mm Hg 716 (7.8) 507 (8.4) 209 (6.5)
S/DBP 140–159/90–99 mm Hg 19908 (20.7) 1,369 (22.7) 539 (16.9)
S/DBP 120–139/80–89 mm Hg 39510 (38.1) 2,328 (38.7) 1,182 (37.0)
S/DBP ,120/,80 mm Hg 39081 (33.4) 1,816 (30.2) 1,265 (39.6)
Education level
Low= Elementary school or apprenticeship 4,429 (48.1) 2,837 (47.1) 1,592 (49.8) 0.01
High =Maturity/baccalaureat or university 4,786 (51.9) 3,183 (52.9 1,603 (50.2)
Swiss citizenship 4,916 (54.2) 3,321 (55.3) 1,595 (52.2) 0.007
Sedentarity 5,863 (63.6) 3,836 (63.7) 2,027 (63.4) 0.79
Alcohol consumption ,0.0001
Lower tertile 3,086 (33.5) 1,963 (32.6) 1,123 (35.1)
Middle tertile 3,073 (33.4) 1,963 (32.6) 1,110 (34.7)
Upper tertile 3,056 (33.2) 2,094 (34.8) 962 (30.19)
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HTN, hypertension.
doi:10.1371/journal.pone.0039877.t001
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Discussion
Hypertension is the most prevalent cardiovascular disorder in
high-income countries, where it affects 20% to 50% of the adult
population [2,22]. In a representative population of adults in
Geneva, the 2004–2009 age-adjusted prevalence of hypertension
were 41.7% and 27.3% in men and women, respectively. These
prevalences are higher than the ones reported in the United States,
but similar to what is found in most European countries [23–28].
This is in line with previous reports showing that hypertension
prevalences are higher in Europe than in North America. Wolf
Maier et al. found that hypertension prevalence was 28% in the
North American countries and 44% in 6 European countries [6].
Our analyses showed no significant changes in hypertension
prevalence in adults from 1999 to 2009. A 1993–2000 analysis
conducted in the same source population reported, a decline in
hypertension prevalence in men and women [29]. It was suggested
that the decline could be attributed to dietary changes such as
changes in salt intake [29]. Salt intake in the Geneva population
has however remained particularly high and stable between 1993
and 2004 [30]. Our results showing an absence of further decline
in hypertension prevalence in recent years are in line with other
major surveys. The most recent NHANES survey reported an
increase in hypertension prevalence followed by a stable preva-
lence around 29% in the 2007–2008 period [4]. Data from the
MONICA studies reported different trends in Belgium, Finland
and Germany; a decline, a stable, and an increase prevalence of
hypertension, respectively [2]. The Health Survey for England
conducted in 1994 and 1998 reported similar prevalence of
hypertension (about 37%) [2]. Thus, much needs to be done to
decrease the burden of hypertension in the canton of Geneva and
population-based strategies, such as reduction of sodium intake,
are of utmost importance.
Hypertension awareness improved between 1999 and2009 in
the Geneva population. Similar favorable trends have been
reported in other, yet scarce, longitudinal reports on hypertension
awareness [5,12,31–33]. In the last period (2004–2009), about
25% of the participants were unaware of having hypertension.
This is lower than most of the estimates reported in other
European cross-sectional studies performed after 2002
[25,26,28,34,35]. Current smoking, male gender, hypercholester-
olemia, and older age were associated with hypertension un-
awareness. Smoking has been consistently described as a barrier to
preventive medicine such as screening, but association between
smoking and hypertension unawareness has rarely been looked at
or found [7,14,16,36]. In a representative sample of the Chinese
population (n= 15 838), higher unawareness was also found, with
the same magnitude as in our study population (OR=1.27) [15].
Men with hypertension were less frequently aware than women,
a finding consistent with the literature [4,7,28,35,37]. It has been
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survey year.
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suggested that the gender difference in awareness is, in part, due to
the more frequent lifetime contact of women with the medical
staff.
Elevated BP is a risk factor for coronary heart disease, heart
failure, stroke, peripheral arterial disease, and renal failure [38–
41]. BP control is adequate when systolic and diastolic BPs are
,140 mm Hg and ,90 mm Hg, respectively [42,43]. Prevalence
of uncontrolled BP in hypertensive patients varied from 10% to
65% across studies [2,24,44–51]. We found that hypertension was
detected but often untreated in the Geneva population. In the last
survey period, the prevalence of untreated hypertension was 58%
in the canton of Geneva, which lies in the upper range of
European’s estimates [25–27,35]. In France, the neighboring
country of Geneva, the prevalence of untreated hypertension was
only 20% in the 2005–2007 MONA LISA [35]. Our data
suggested that untreated hypertension has been stable since 1999.
The substantial decrease in hypertension unawareness between
1999–2003 and 2004–2009 was therefore not paralleled by
a concomitant absolute increase in hypertension treatment. As
a consequence, a larger proportion of all hypertensive participants
were aware but not treated in 2004–2009 (43.7%) compared to
1999–2003 (33.1%) (Figure S2). The observed gain in hyperten-
sion awareness is therefore unlikely to translate into public health
benefit if no action is undertaken to control BP. We found that BP
was not controlled in half of hypertensive treated subjects, which
corresponds to the control rate reported in 2009 in a Swiss city
population-based study (48%) [7].
Hypertension treatment initiation and intensification once
hypertension is detected are challenged by both patient- and
physician-related factors, which may vary across regions [52].
Outclinic patients with inadequately controlled hypertension
seemed to be less likely to receive a medication increase in the
United States than in European countries [53]. In Switzerland,
information on reasons for untreated and/or uncontrolled
hypertension is limited. In a family practice based, open
intervention survey, physicians-related reasons for uncontrolled
BP were to believe that baseline BP dictates the target, that a clear
improvement in BP might be sufficient and that the full drug effect
may take up to 4 months or more to be achieved [54]. Here, we
provide information on patients-related characteristics of un-
treated and uncontrolled hypertension. This needs to be complet-
ed by additional patient- and physician-based studies conducted in
Switzerland.
After adjustment, participants with high education level were at
increased risk of untreated hypertension than participants with
lower level of education. The associations between education and
hypertension awareness, treatment and control are inconsistent.
Some reports showed an inverse association or no association
between education level and hypertension awareness, treatment or
control [16]. In line with our results, untreated hypertension was
positively associated with high education level in four Scottish
MONICA cross-sectional surveys (1986, 1989, 1992 and 1995)
[55]. Reason for this unexpected, yet replicated, association is not
clear. It has been suggested that people with high education level
might think they are able to manage their BP and might therefore
not follow their GP’s advice. Because such interventions are highly
dependent on educational level and motivation, we propose that,
conversely, nonpharmacological lifestyle interventions might be
more often presented by GP’s to better educated subjects.
Our results have to be interpreted within the context of the
Swiss health care system. Health insurance is compulsory for all
citizens of Switzerland (7 millions) and insurance premiums are
paid independently of earnings [56,57]. Subsidies are paid for
citizens with low income. Health insurance covers the costs of
medical treatment and hospitalisation of the insured. Everyone
pays part of the cost of treatment through 1) an annual flat
deductible, called the ‘franchise’, which ranges from CHF 300 to
a maximum of CHF 2,500 (1CHF < 1$ < 1.35J), at the insured
person’s choice (premiums are adjusted accordingly); and 2) a 10%
deductible of the costs up to a stop-loss amount of CHF 700 per
year. Some 40% of the Swiss population chooses to top up their
insurance coverage with private health insurance, which offers
a wider choice of treatments and health care professionals, or more
comfortable accommodation during a hospital stay. In contrast to
basic insurance, insurers may refuse applicants for private
insurance or only accept them subject to conditions. While all
basic insurances will cover medical (primary care and specialist)
consultations as well as anti-hypertensive treatment, the insured
still pays 10% of the cost (i.e. out-of pocket participation).
Switzerland has the highest out of pocket participation within
countries of the Organisation for Economic Co-operation and
Development [58]. Thus, even though the Swiss health care
insurance coverage is universal, patient’s financial ressources may
still influence the use of medical services and treatment. Yet, we
found no independent associations between monthly household
income – a proxy of an individual financial resources – and
hypertension, awareness, treatment, or control.
Strengths and Limitations
When interpreting the findings of this study, one has to keep in
mind its limitations. Non participants slightly differed from
participants with respect to sex, age and Swiss citizenship. Given
that our results suggested that age, smoking status and gender are
significant predictors of study outcomes, these differences may
somewhat limit the generalisability of our findings. Several
informations were determined by the use of questionnaires. By
nature of its reliance on self-reported data, this is a source of
possible bias. Similarly to other large population-based studies,
white coat effect, white coat hypertension, or masked hypertension
could not be determined in this analysis. BP was measured with
two different methods; mercury sphygmanometer (1999–2003)
and semi-automatic oscillometer (2004–2009). Although semi-
automatic oscillometer are calibrated with mercury sphygman-
ometer, we cannot exclude that some of the differences observed
between the two periods are attributable to the method of BP
measurement. Yet, it is also possible that the 2003 antihyperten-
sion guidelines (e.g. the 2003 Seventh Joint National Committee
(JNCVII) [10], the 2003 World Health Organization (WHO)/
International Society of Hypertension (ISH) and European
statement on management of hypertension [11]) contributed to
improve the levels of awareness and adherence of the medical staff
to hypertension screening and control. The study which was
conducted concomitantly to the Bus Sante´ study between 2005
and 2008 was a follow-up study involving different independent
participants than the Bus Sante´ study. During this period, only
a smaller number of subjects from the Geneva population were
randomly selected and invited to participate to the Bus Sante´
study. The study protocole and procedures remained identical.
Yet, we cannot exclude some interference between the two studies.
The strengths of this study are the secular comparison of
prevalences using the same definition, in the same source
population, using the same number of BP readings. In addition,
the large number of included subjects (.99000), the recruitment
strategy of the participants (representative sampling and low
attrition), the time window (ten years with yearly data), and the
inclusion of objective measures strengthen the findings.
In conclusion, in a representative sample of the canton of
Geneva, Switzerland, the prevalence of hypertension remained
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stable between 1999–2003 and 2004–2009. Population-based
primary prevention measures are needed to decrease the burden of
hypertension in this region. While favorable trends in hypertension
unawareness and uncontrolled hypertension occurred during this
period, about half of hypertensive subjects were not treated or had
uncontrolled high BP in the latest 2004–2009 survey period.
Factors associated with untreated and uncontrolled hypertension
in our analyses could guide the implementation of targeted
interventions aimed at reducing these rates.
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